1. Scrip
  2. >>Business

More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab

 
• By Anju Ghangurde

Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.

Rio
MYLAN-BIOCON HAVE RECEIVED APPROVAL FOR THEIR HERCEPTIN BIOSIMILAR IN BRAZIL

Biocon Ltd. and partner Mylan NV have ended 2017 with another regulatory win, after Brazil’s Anvisa approved their biosimilar Herceptin (trastuzumab).

The approval, which marks the arrival of the first biosimilar trastuzumab in the Latin American nation, came through Libbs Farmaceutica,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.